Skip to content
Clinical Trials – home
Not yet recruiting

Effect of Adding Dasatinib to Semaglutide on Metabolic Health in Adults with Uncontrolled Type 2 Diabetes

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on adults with type 2 diabetes whose blood sugar control remains insufficient despite standard therapy. Participants will continue their usual medication and will receive either the investigational drug dasatinib taken by mouth, the background medication semaglutide injected under the skin, or a matching placebo. The goal is to see whether adding the senolytic agent dasatinib can lower markers of cellular senescence (the process where cells stop dividing and can cause tissue problems) and inflammation (the body’s response that can damage tissues), and improve glucose tolerance (how well the body handles sugar after a meal).

During the trial, participants will attend regular visits over about 20 weeks. At the start and at the end, small samples of fat and muscle tissue will be taken to measure senescence markers, and blood samples will be checked for related proteins. A sugar‑drink test will be performed to assess how quickly blood sugar rises and falls, while a wearable device will record daily glucose patterns. Standard laboratory tests will track changes in HbA1c (average blood sugar over the past few months), insulin sensitivity (how well the body responds to insulin), and beta-cell function (the ability of the pancreas to release insulin). Participants will also complete quality‑of‑life questionnaires to capture any changes in overall well‑being.

The research process

The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessment

    You will attend a first visit after joining the study where the research team will confirm that you meet the study requirements and will collect basic health information.

    During this visit, tissue samples from subcutaneous fat and muscle, as well as blood samples, will be taken to measure markers of cellular senescence and inflammation.

    You will also complete questionnaires about your health and quality of life, and an oral glucose tolerance test will be performed to assess how your body handles sugar.

  2. Step 2

    Start Background Medication – Semaglutide

    You will begin using semaglutide, a medication that helps control blood sugar. It is supplied as a 0.14 mg solution for injection in a pre‑filled pen.

    The injection is given under the skin (subcutaneous use) and will be administered once a week for the entire 20‑week treatment period.

    The purpose of semaglutide is to improve your glucose control while the study drug is being tested.

  3. Step 3

    Randomization and Start of Study Drug

    After the baseline visit, you will be randomly assigned to receive either the active study drug or a matching placebo.

    If assigned to the active group, you will take dasatinib, a senolytic agent that targets aged or damaged cells. The tablet is film‑coated and taken by mouth.

    If assigned to the placebo group, you will take an identical tablet that contains no active medication.

  4. Step 4

    Study Drug Administration

    You will take one tablet each day, containing either 100 mg of dasatinib or a placebo, for a total duration of 20 weeks.

    The tablet should be swallowed with water and can be taken with or without food.

    Daily dosing will continue for the entire treatment period unless a serious safety issue occurs.

  5. Step 5

    Ongoing Monitoring Visits

    You will return to the clinic at regular intervals (for example, weeks 4, 8, 12, and 20) for safety checks, blood draws, and questionnaire completion.

    During each visit, the team will measure blood glucose, HbA1c (a marker of average blood sugar), and other laboratory values to monitor your response to the medications.

    You will also be asked to report any side effects or new health problems.

  6. Step 6

    Oral Glucose Tolerance Test

    An oral glucose tolerance test will be repeated at the end of the 20‑week period.

    You will drink a sugary solution, and blood samples will be taken over several hours to see how well your body processes glucose.

    The result will be compared with the baseline test to evaluate any improvement.

  7. Step 7

    Continuous Glucose Monitoring

    During predefined periods (for example, the first two weeks and the last two weeks of treatment), you will wear a small device that continuously measures glucose levels under the skin.

    The device records mean glucose levels and how much glucose fluctuates, providing detailed information about your daily glucose control.

    Data from the device will be used to assess the effect of the study drug on glucose variability.

  8. Step 8

    Questionnaire Completion

    At baseline and at week 20, you will complete the RAND‑36 and EQ‑5D‑5 questionnaires, which evaluate your physical and mental health and overall quality of life.

    These responses will be compared to see whether the treatment has any impact on your well‑being.

  9. Step 9

    Final Assessment and End of Treatment

    At the end of the 20‑week period, you will undergo a final clinic visit that includes the last set of blood and tissue samples, the repeat oral glucose tolerance test, and removal of the continuous glucose monitoring device.

    All study medications will be stopped after this visit, and you will receive a summary of the assessments performed during the trial.

Who can join the trial?

7 criteria

  • Be between 40 and 75 years old at the time you join the study.
  • Have a confirmed diagnosis of type 2 diabetes for at least one year.
  • Show an HbA1c level (a blood test that reflects average sugar over the past few months) between 6.5% and 10.0% (47–86 mmol/mol) when screened.
  • Have a body mass index (BMI) (a measure of weight compared to height) between 27 and 40 kg/m².
  • Be using stable glucose‑lowering therapy (medicines that help control blood sugar), including being eligible for the medication semaglutide, for at least three months before screening.
  • Be willing and able to follow study procedures, such as an oral glucose tolerance test (drinking a sugary liquid while blood sugar is measured), a tissue biopsy (small sample of tissue taken for analysis), regular blood sampling, and continuous glucose monitoring (a device that tracks sugar levels continuously).
  • Be able to sign a written informed consent form.

Who cannot join the trial?

14 criteria

  • Type 1 diabetes or other specific forms of diabetes.
  • Unstable or poorly controlled medical conditions that could increase risk or interfere with the study.
  • Significant heart disease, including arrhythmias (irregular heartbeats) or conditions that can cause a heart rhythm problem called QT prolongation.
  • Autoimmune disease that requires medicines that suppress the immune system.
  • Active or recent cancer, except well‑treated non‑melanoma skin cancer.
  • Severe kidney problems or important liver disease.
  • Bleeding disorders, low platelet count (thrombocytopenia), or use of blood‑thinning medicines that cannot be safely stopped.
  • Active infection, including chronic viral hepatitis or known hepatitis B infection.
  • Use of medicines that strongly block or increase the activity of the enzyme CYP3A4, or other drugs that should not be taken with dasatinib.
  • Use of proton pump inhibitors or H2‑receptor antagonists that cannot be stopped or replaced as required by the study.
  • Known allergy to semaglutide, dasatinib, or any ingredients in the study medication.
  • Pregnancy, breastfeeding, or women who could become pregnant and are not using reliable birth control.
  • Participation in another interventional clinical trial within a set time before screening.
  • Any other condition that the doctor believes would make participation unsafe or affect the study results.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Dasatinib

    is a medication that helps remove damaged or aged cells, known as senescent cells, from the body. In this study, participants will take dasatinib in addition to their usual diabetes treatment to see if it can lower inflammation and improve how the body handles sugar. Researchers hope that by clearing these unhealthy cells, the drug may help protect the pancreas and improve overall blood‑sugar control in people with type 2 diabetes.

  • Semaglutide

    is a medicine that is already used to treat type 2 diabetes. It is given as a tiny injection under the skin and works by helping the pancreas release more insulin after meals, reducing the amount of sugar the liver makes, and slowing down how quickly food leaves the stomach. In this trial, semaglutide is used as the background therapy so that all participants have a standard diabetes treatment while the study tests whether adding dasatinib provides extra benefit.

What is already known about the treatment

  • Dasatinib

    Dasatinib is taken as a film‑coated tablet that is swallowed by mouth. It is an approved cancer medicine that is now being studied for its ability to remove old, harmful cells that contribute to inflammation. Its main use is for certain types of leukemia, and it works by blocking signals that tell damaged cells to keep growing. It belongs to the class of tyrosine‑kinase inhibitors and is considered a senolytic agent in research.

  • Semaglutide

    Semaglutide is provided as a liquid that is injected under the skin using a pre‑filled pen. It is a widely approved treatment for type 2 diabetes and also for weight management. It works by mimicking a natural hormone that helps the pancreas release insulin and reduces appetite. It is classified as a GLP‑1 receptor agonist.

Investigated diseases

Type 2 diabetes mellitus - It is a long‑lasting condition in which the body’s cells become less responsive to insulin, the hormone that helps glucose enter cells. As a result, blood sugar levels rise and the pancreas eventually produces less insulin. The disease usually begins with mild insulin resistance and progresses to increasingly higher glucose levels if not controlled. Over time, the elevated sugar can affect many organs, leading to changes in metabolism and tissue function.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-525186-41-01Estimated enrolment40 patientsSponsorAmsterdam UMC Stichting

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.